KCHEK ORAL SACHETS

Indications

• Hyperkalemia
• Chronic kidney disease with elevated potassium levels
• Management of certain toxicities (e.g., digoxin toxicity) in conjunction with other treatments

Dosage

Children: Refer to established clinical guidelines for specific pediatric dosing information, as it is based on weight and clinical condition.

Adults: Refer to established clinical guidelines for specific dosing information, as it may vary based on the severity of hyperkalemia and the clinical setting.

Mechanism of action

Sodium polystyrene sulfonate acts as a cation-exchange resin in the intestines, where it exchanges sodium ions for potassium ions. This process facilitates the elimination of potassium from the body through feces, effectively lowering serum potassium concentrations.

Pharmacodynamics

The primary pharmacodynamic effect of sodium polystyrene sulfonate is the reduction of serum potassium levels. The resin binds potassium in the gastrointestinal tract, leading to an increase in potassium excretion. The onset of action can vary; however, the drug generally takes several hours to exert its effects, with peak potassium-lowering effects occurring after a few hours.

Pharmacokinetics

Sodium polystyrene sulfonate is not absorbed systemically; its action is confined to the gastrointestinal tract. The resin passes through the intestines unaltered and is excreted in feces. The duration of action is dependent on the amount of potassium present in the gut and the total resin dose administered. Its elimination is essentially through fecal excretion.

Contra-indications

• Hypokalemia
• Severe gastrointestinal obstruction
• Bowel perforation

Adverse effects

• Electrolyte disturbances
• Gastrointestinal irritation
• Constipation
• Nausea
• Vomiting
• Abdominal discomfort

Interactions

• May decrease the absorption of certain medications due to delayed gastric emptying
• Caution when used with other medications that can affect potassium levels

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolyte levels during therapy
• Ensure adequate hydration to prevent constipation

Pregnancy

Use only if clearly needed and after assessing potential benefits versus risks, as safety during pregnancy has not been fully established.

Breast-feeding

It is not known if polystyrene is excreted in human milk. Use with caution and assess the necessity.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Polystyrene sulfonate (sodium or calcium) in powder form
• Polystyrene sulfonate suspension

Mechanism of action

Sulphonates exert their effects primarily through the inhibition of certain enzymes or pathways involved in metabolic processes. They may interact with cellular receptors or transporters, leading to alterations in ion transport, enzyme activity, and cellular signaling.

Pharmacodynamics

The pharmacodynamics of sulphonates is largely dependent on their specific structure and the biological targets they interact with. Generally, they may modulate the activity of neurotransmitters, influence the reactivity of free radicals, or affect cellular signaling pathways, contributing to their therapeutic effects.

Pharmacokinetics

Sulphonates are typically absorbed in the gastrointestinal tract, with variable bioavailability depending on the specific compound. They are metabolized primarily in the liver, with subsequent elimination through renal pathways. The half-life and clearance can vary significantly based on the compound's structure and the individual's physiology.